Synergistic influence of Abcb1 and Abcc2 on disposition and sterol lowering effects of ezetimibe in rats

Journal of Pharmaceutical Sciences

Volumn 99, Issue 1, 2010, Pages 422-429

  Oswald, Stefan ^a   May, Karen ^a   Rosin, Juliane ^a   Lütjohann, Dieter ^b   Siegmund, Werner ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

ABCB1; ABCC2; Disposition; Ezetimibe; MRP2; P gp; PSC833; Transporter

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER C2; CAMPESTEROL; CHOLESTEROL; EZETIMIBE; EZETIMIBE GLUCURONIDE; GLUCURONIDE; MULTIDRUG RESISTANCE PROTEIN 1; SITOSTEROL; UNCLASSIFIED DRUG; VALSPODAR;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG EXCRETION; DRUG FECES LEVEL; MALE; NONHUMAN; PROTEIN FUNCTION; RAT; URINARY EXCRETION; WILD TYPE;

EID: 73949151893     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21821     Document Type: Article

References (29)

1. Nies AT, Schwab M, Keppler D. 2008. Interplay of conjugating enzymes with OATP uptake transporters and ABCC/MRP efflux pumps in the elimination of drugs. Expert Opin Drug Metab Toxicol 4:545-568.
2. Jeong EJ, Liu X, Jia X, Chen J, Hu M. 2005. Coupling of conjugating enzymes and efflux transporters: Impact on bioavailability and drug interactions. Curr Drug Metab 6:455-468.
3. Zamek-Gliszczynski MJ, Hoffmaster KA, Nezasa K, Tallman MN, Brouwer KL. 2006. Integration of hepatic drug transporters and phase II metabolizing enzymes: Mechanisms of hepatic excretion of sulfate, glucuronide, and glutathione metabolites. Eur J Pharm Sci 27:447-486.
4. Sweeney ME, Johnson RR. 2007. Ezetimibe: An update on the mechanism of action, pharmacokinetics and recent clinical trials. Expert Opin Drug Metab Toxicol 3:441-450.
5. Kosoglou T, Statkevich P, Johnson-Levonas AO, Paolini JF, Bergman AJ, Alton KB. 2005. Ezetimibe: A review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet 44:467-494.
6. Oswald S, Haenisch S, Fricke C, Sudhop T, Remmler C, Giessmann T, Jedlitschky G, Adam U, Dazert E, Warzok R, Wacke W, Cascorbi I, Kroemer HK, Weitschies W, von Bergmann K, Siegmund W. 2006. Intestinal expression of P-glycoprotein (ABCB1), multidrug resistance associated protein 2 (ABCC2), and uridine diphosphate-glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans. Clin Pharmacol Ther 79:206-217.
7. Oswald S, Konig J, Lutjohann D, Giessmann T, Kroemer HK, Rimmbach C, Rosskopf D, Fromm MF, Siegmund W. 2008. Disposition of ezetimibe is influenced by polymorphisms of the hepatic uptake carrier OATP1B1. Pharmacogenet Genomics 18:559-568.
8. Oswald S, Giessmann T, Luetjohann D, Wegner D, Rosskopf D, Weitschies W, Siegmund W. 2006. Disposition and sterol-lowering effect of ezetimibe are influenced by single-dose coadministration of rifampin, an inhibitor of multidrug transport proteins. Clin Pharmacol Ther 80:477-485.
9. Oswald S, Westrup S, Grube M, Kroemer HK, Weitschies W, Siegmund W. 2006. Disposition and sterol-lowering effect of ezetimibe in multidrug resistance-associated protein 2-deficient rats. J Pharmacol Exp Ther 318:1293-1299.
10. Oswald S, Koll C, Siegmund W. 2007. Disposition of the cholesterol absorption inhibitor ezetimibe in mdr1a/b (-/-) mice. J Pharm Sci 96:3478-3484.
11. Jette L, Murphy GF, Beliveau R. 1998. Drug binding to P-glycoprotein is inhibited in normal tissues following SDZ-PSC 833 treatment. Int J Cancer 76:729-737.
12. Kankesan J, Vanama R, Yusuf A, Thiessen JJ, Ling V, Rao PM, Rajalakshmi S, Sarma DS. 2004. Effect of PSC 833, an inhibitor of P-glycoprotein on Nmethyl-N-nitrosourea induced mammary carcinogenesis in rats. Carcinogenesis 25:425-430.
13. Oswald S, Scheuch E, Cascorbi I, Siegmund W. 2006. A LC-MS/MS method to quantify the novel cholesterol lowering drug ezetimibe in human serum, urine and feces in healthy subjects genotyped for SLCO1B1. J Chromatogr B Analyt Technol Biomed Life Sci 830:143-150.
14. Thelen KM, Laaksonen R, Paiva H, Lehtimaki T, Lutjohann D. 2006. High-dose statin treatment does not alter plasma marker for brain cholesterol metabolism in patients with moderately elevated plasma cholesterol levels. J Clin Pharmacol 46:812-816.
15. Ghosal A, Hapangama N, Yuan Y, Achanfuo-Yeboah J, Iannucci R, Chowdhury S, Alton K, Patrick JE, Zbaida S. 2004. Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of ezetimibe (Zetia). Drug Metab Dispos 32:314-320.
16. van Heek M, Farley C, Compton DS, Hoos L, Alton KB, Sybertz EJ, Davis HR, Jr. 2000. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. Br J Pharmacol 129:1748-1754.
17. Bergman AJ, Burke J, Larson P, Johnson-Levonas AO, Reyderman L, Statkevich P, Maxwell SE, Kosoglou T, Murphy G, Gottesdiener K, Robson R, Paolini JF. 2006. Interaction of single-dose ezetimibe and steady-state cyclosporine in renal transplant patients. J Clin Pharmacol 46:328-336.
18. Gustavson LE, Schweitzer SM, Burt DA, Achari R, Rieser MJ, Edeki T, Chira T, Yannicelli HD, Kelly MT. 2006. Evaluation of the potential for pharmacokinetic interaction between fenofibrate and ezetimibe: A phase I, open-label, multiple-dose, threeperiod crossover study in healthy subjects. Clin Ther 28:373-387.
19. Reyderman L, Kosoglou T, Statkevich P, Pember L, Boutros T,Maxwell SE. 2004. Assessment of amultible-dose drug interaction between ezetimibe, a novel selective cholesterol absorption inhibitor and gemfibrozil. Int J Clin Pharmacol Ther 42: 512-518.
20. Food and Drug Administration (FDA). 2002. Approval documentation of Zetia (ezetimibe): Pharmacology Review, part 2. http://wwwfda.gov/cder/foi/nda/2002/ 21445-Zetia htm.
21. Newton DJ, Wang RW, Evans DC. 2005. Determination of phase I metabolic enzyme activities in liver microsomes of Mrp2 deficient TR- and EHBR rats. Life Sci 77:1106-1115.
22. Silva VM, Thibodeau MS, Chen C, Manautou JE. 2005. Transport deficient (TR-) hyperbilirubinemic rats are resistant to acetaminophen hepatotoxicity. Biochem Pharmacol 70:1832-1839.
23. Leslie EM, Ghibellini G, Nezasa K, Brouwer KL. 2007. Biotransformation and transport of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3- pyridyl)-1-butanone (NNK) in bile duct-cannulated wild-type and Mrp2/Abcc2-deficient (TR) Wistar rats. Carcinogenesis 28:2650-2656.
24. Miettinen TA, Tilvis RS, Kesaniemi YA. 1990. Serum plant sterols and cholesterol precursors reflect cholesterol absorption and synthesis in volunteers of a randomly selected male population. Am J Epidemiol 131:20-31.
25. Johnson BM, Zhang P, Schuetz JD, Brouwer KL. 2006. Characterization of transport protein expression in multidrug resistance-associated protein (mrp) 2-deficient rats. Drug Metab Dispos 34: 556-562.
26. Chen ZS, Kawabe T, Ono M, Aoki S, Sumizawa T, Furukawa T, Uchiumi T, Wada M, Kuwano M, Akiyama SI. 1999. Effect of multidrug resistancereversing agents on transporting activity of human canalicular multispecific organic anion transporter. Mol Pharmacol 56:1219-1228.
27. Lehne G, Morkrid L, den Boer M, Rugstad HE. 2000. Diverse effects of P-glycoprotein inhibitory agents on human leukemia cells expressing the multidrug resistance protein (MRP). Int J Clin Pharmacol Ther 38:187-195.
28. Modok S, Mellor HR, Callaghan R. 2006. Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer. Curr Opin Pharmacol 6:350-354.
29. Cao X, Gibbs ST, Fang L,Miller HA, Landowski CP, Shin HC, Lennernas H, Zhong Y, Amidon GL, Yu LX, Sun D. 2006. Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharm Res 23:1675-1686.